Department of Gastrointestinal, Hepatobilliary & Pancreatic Disorders, Bangladesh Institute of Research and Rehabilitation for Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Shahbag, Dhaka, Bangladesh
Department of Surgery, Bangladesh Institute of Research and Rehabilitation for Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Shahbag, Dhaka, Bangladesh
Department of Gastroenterology, BRB Gastroliver Hospital, Dhaka, Bangladesh
objectives:Gastrointestinal stromal tumor (GISTs) is an uncommon and rare
disease in Bangladesh. Our aims were to describe
socio-demographic characteristics, clinical presentations, anatomical location,
morphological variation, treatment and outcome of GIST in ten cases.
Methods:This study included consecutive ten cases of GISTs diagnosed
and treated in two tertiary level hospitals in Dhaka, Bangladesh from 2013 to
2016. Patients’ socio-demographic characteristics, clinical presentations,
anatomical location, histological types, presence of CD117 markers were
determined. Outcome of the treatment by surgical intervention and imatinib mesylate
(400mg/day) were evalauted.
Results: Total 10 patients were included in the study. Among them 6 were
male and 4 were female. The age range was 32-74 years. Abdominal pain, haematemesis,
melaena, haematochezia and anaemia
were the most common presentation. One patient had dysphagia and another had
features of subacute intestinal obstruction. Five patients had GIST in the
stomach (50%), two had in colon and one in esophagus, duodenum and ileum
respectively. CD 117 was positive in 8 cases, majority had spindly type cell
with low mitotic figure. Imatinib therapy was given in all the cases except two
patients. Disease recurrence in the form liver metastasis was found in two
cases and both died. Disease free survival for more than 2 years was observed
in 4 cases.
Conclusion: Haematemesis and melaena were common presentation of GISTs.
Stomach was the most common site for GISTs and majority had spindle type of
cells and positive CD117 marker. Surgical intervention and imatinib therapy was
IMC J Med
Sci 2017; 11(2): 45-49